Research Topics
| Andrew J K OstorSummaryAffiliation: Addenbrooke's Hospital Country: UK Publications
| Collaborators
|
Detail Information
Publications
Interrater reproducibility of clinical tests for rotator cuff lesionsA J K Ostor
Rheumatology Research Unit, Box 194, Hills Road, Cambridge CB2 2QQ, UK
Ann Rheum Dis 63:1288-92. 2004..Rotator cuff lesions are common in the community but reproducibility of tests for shoulder assessment has not been adequately appraised and there is no uniform approach to their use...
Pulmonary complications of infliximab therapy in patients with rheumatoid arthritisAndrew J K Ostor
Rheumatology Department, Addenbrooke s Hospital, Cambridge, UK
J Rheumatol 33:622-8. 2006....
The murky waters of the coxibs: a review of the current state of playAndrew J K Ostor
Rheumatology Research Unit, Addenbrooke s Hospital, Hills Road, Cambridge CB2 2QQ, UK
Inflammopharmacology 13:371-80. 2005..This article will attempt to review the data regarding coxibs and make some recommendations regarding their ongoing use...
Diagnosis and relation to general health of shoulder disorders presenting to primary careA J K Ostor
Rheumatology Research Unit, Box 194, Addenbrooke s Hospital, Hills Road, Cambridge CB2 2QQ, UK
Rheumatology (Oxford) 44:800-5. 2005..To prospectively evaluate the incidence, spectrum of disease and relation to general health of shoulder disorders in primary care...
Fatal exacerbation of rheumatoid arthritis associated fibrosing alveolitis in patients given infliximabAndrew J K Ostor
Department of Rheumatology, Addenbrooke's Hospital, Cambridge CB2 2QQ
BMJ 329:1266. 2004
Abatacept: a T-cell co-stimulation modulator for the treatment of rheumatoid arthritisAndrew J K Ostor
Addenbrooke s Hospital, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK
Clin Rheumatol 27:1343-53. 2008..Taken together, these data suggest that selective co-stimulation modulation with abatacept may be a viable option for patients who are refractory to both traditional therapies and TNF-alpha antagonists...
Tumour necrosis factor antagonists and the risk of cardiovascular disease in patients with rheumatoid arthritis: a systematic literature reviewSarah L Westlake
Department of Rheumatology, Southampton General Hospital, Tremona Road, Southampton SO16 6YD, UK
Rheumatology (Oxford) 50:518-31. 2011..However, the extent to which these agents also reduce cardiovascular disease (CVD) is uncertain. The purpose of this study was to explore the effect of anti-TNF agents on CVD in RA using a systematic literature review...
The effect of methotrexate on cardiovascular disease in patients with rheumatoid arthritis: a systematic literature reviewSarah L Westlake
Department of Rheumatology, Poole Hospital NHS Foundation Trust, Poole, UK
Rheumatology (Oxford) 49:295-307. 2010..This is due to traditional risk factors and the effects of chronic inflammation. MTX is the first-choice DMARD in RA. We performed a systematic literature review to determine whether MTX affects the risk of CVD in patients with RA...
Risk of adverse events including serious infections in rheumatoid arthritis patients treated with tocilizumab: a systematic literature review and meta-analysis of randomized controlled trialsLaura Campbell
Department of Medicine, Clinical School, University of Cambridge, Cambridge CB2 0QQ, UK
Rheumatology (Oxford) 50:552-62. 2011..To assess the risk of adverse events (AEs) in patients with RA treated with tocilizumab, an IL-6 receptor antibody, in published randomized controlled trials (RCTs)...
Contemporary treatment principles for early rheumatoid arthritis: a consensus statementPatrick D W Kiely
Department of Rheumatology, St Georges Healthcare NHS Trust, London, UK
Rheumatology (Oxford) 48:765-72. 2009..RA has a substantial impact on both patients and healthcare systems. Our objective is to advance the understanding of modern management principles in light of recent evidence concerning the condition's diagnosis and treatment...
Immune-mediated inflammatory diseases (IMIDs) and biologic therapy: a medical revolutionAnnabel Kuek
Rheumatology Research Unit, Addenbrooke s Hospital, Cambridge, UK
Postgrad Med J 83:251-60. 2007..For the medical profession, IMID represents a breakthrough in the way pathology is classified. In this burgeoning era of biologic therapy the prospect of complete disease remission is conceivable...
Biologic agents for rheumatoid arthritis--negotiating the NICE technology appraisalsPatrick D W Kiely
Department of Rheumatology, St Georges Healthcare NHS Trust, London SW17 0QT, UK
Rheumatology (Oxford) 51:24-31. 2012..In this review, we discuss the treatment algorithm published by NICE, and suggest alternatives where perceived deficiencies exist...
Non-infectious pulmonary complications of newer biological agents for rheumatic diseases--a systematic literature reviewAndreas V Hadjinicolaou
Rheumatology Research Unit, Box 194, Addenbrooke s Hospital, CUHNHSFT, Cambridge CB2 2QQ, UK
Rheumatology (Oxford) 50:2297-305. 2011..As the use of these drugs increases, clinicians must remain vigilant for potential pulmonary complications and exercise caution in prescribing biologic therapies, particularly to rheumatological patients with pre-existing ILD...
Disease remission the goal of therapy in rheumatoid arthritisMuhammad K Nisar
Addenbrooke s Hospital, Cambridge
Practitioner 254:17-21, 2. 2010....
Lower gastrointestinal perforation in rheumatoid arthritis patients treated with conventional DMARDs or tocilizumab: a systematic literature reviewTaras Gout
School of Clinical Medicine, University of Cambridge, Cambridge, UK
Clin Rheumatol 30:1471-4. 2011..The mechanism of action of IL-6 antagonism in the pathophysiology of diverticular perforation has yet to be elucidated...
Early diagnosis crucial in ankylosing spondylitisAnshuman P Malaviya
Rheumatology Clinical Research Unit, Addenbrooke s Hospital, Cambridge
Practitioner 255:21-4, 2. 2011..However, about half these patients need escalation to biologic therapy. Patients with a suspected diagnosis should be referred to secondary care in order to confirm the diagnosis and commence treatment...
Rheumatoid arthritis and the era of biologic therapyAnshuman P Malaviya
School of Clinical Medicine, University of Cambridge, Cambridge, UK
Inflammopharmacology 20:59-69. 2012..In addition, we will provide a commentary on the current limitations and unmet needs in this area and discuss the future of biologic intervention...
Diagnosing joint pain in the older peopleShweta Bhagat
Rheumatology Clinical Research Unit, Addenbrooke s Hospital, Cambridge
Practitioner 254:17-21, 2. 2010..Corticosteroids may be very effective in the elderly, however, prolonged use and/or high dosage may lead to marked toxicity especially osteoporosis and diabetes...
Necrotizing group A streptococcal periorbital infection following adalimumab therapy for rheumatoid arthritisJonathan C P Roos
Department of Medicine, University of Cambridge, Cambridge, UK
Cutan Ocul Toxicol 30:160-2. 2011..2) To identify bacterial species responsible for infection with different forms of biological therapy...
Orbital cellulitis in a patient receiving infliximab for Ankylosing spondylitisJonathan C P Roos
Department of Medicine, University of Cambridge, Cambridge, United Kingdom
Am J Ophthalmol 141:767-9. 2006..To describe a case of orbital cellulitis arising in a patient treated with an anti-TNFalpha agent...
Interstitial pneumonitis and anti-tumor necrosis factor-alpha therapyJonathan C P Roos
J Rheumatol 34:238-9; author reply 239. 2007
Anti-tumor necrosis factor alpha therapy and the risk of JC virus infectionJonathan C P Roos
Arthritis Rheum 54:381-2. 2006
Neurological complications of infliximabJonathan C P Roos
J Rheumatol 34:236-7; author reply 237-8. 2007
Sarcoid-like granulomatous disease following etanercept treatment for RAAlex Kudrin
J Rheumatol 34:648-9. 2007
